Guidant’s last stand on paclitaxel
This article was originally published in The Gray Sheet
Executive Summary
Company's paclitaxel-eluting stent program achieves closure with federal appeals court affirmation of lower court ruling that Cook's deal with Guidant violated a co-exclusive license agreement among Boston Scientific, Cook and Angiotech. The program already had been terminated due to poor DELIVER study results; in January, Guidant scuttled a proposed merger with Cook. Guidant is exploring an everolimus-eluting stent (1"The Gray Sheet" Jan 6, 2003, p. 4). Boston Scientific submits the fifth and final PMA module for its Taxus paclitaxel-eluting stent...